Vir Biotechnology offers an AI‑driven antibody discovery platform integrated with its PRO‑XTEN protease‑cleavable masking technology to produce high‑affinity antibodies and bispecific T‑cell engagers. The combined approach accelerates development of targeted immunotherapies for chronic infectious diseases and oncology while minimizing off‑target toxicity and extending half‑life. The company licenses these capabilities to pharmaceutical and biotech partners for their therapeutic programs.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with chronic infectious diseases and certain cancers lack effective, targeted therapies, and existing treatments often cause off‑target toxicity or are evaded by pathogens and tumor cells. This therapeutic gap leads to high morbidity and limited clinical options for these high‑unmet‑need populations.
Solution
Vir Biotechnology applies a next‑generation antibody discovery platform combined with advanced protein‑engineering and artificial‑intelligence tools (dAIsY™) to generate high‑affinity antibodies and T‑cell engagers. The proprietary PRO‑XTEN® protease‑releasable masking technology cloaks potent molecules until they reach the disease microenvironment, reducing systemic exposure and improving safety. By integrating AI‑driven design, rapid optimization, and masking, the company accelerates candidate progression from concept to clinic across infectious disease and oncology indications. Clinical‑stage programs target chronic hepatitis delta, solid‑tumor antigens (HER2, PSMA, EGFR), and preclinical HIV candidates, aiming to deliver transformative immunotherapies that harness the patient’s own immune system.
Target Audience
Primary customers are pharmaceutical and biotech companies, as well as clinical research organizations, seeking novel antibody‑based therapeutics and T‑cell engager platforms for infectious disease and oncology programs.
Features
- High‑throughput antibody discovery pipeline leveraging AI‑guided sequence optimization for affinity and developability.
- PRO‑XTEN® masking platform that provides protease‑cleavable concealment of active sites, extending half‑life and minimizing off‑target toxicity.
- T‑cell engager engineering capability to create bispecific molecules that redirect cytotoxic T cells toward tumor or infected cells.
- Integrated dAIsY™ data‑AI framework for rapid in silico modeling of antibody‑antigen interactions and pharmacokinetic properties.
- Exclusive licensing rights to PRO‑XTEN® for both oncology and infectious disease applications, enabling broad therapeutic versatility.
- Robust preclinical and clinical pipeline spanning chronic hepatitis delta, HER2‑positive solid tumors, PSMA‑targeted cancers, EGFR‑driven malignancies, and HIV cure research.
- Strategic collaborations with leading academic institutions, biotech partners, and government agencies to accelerate discovery and regulatory pathways.